Pamiparib: First Approval.

Abstract

Pamiparib (PARTRUVIX™; BeiGene Ltd.) is a selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor being developed for the treatment of various cancers. Based on the results from the pivotal phase II portion of a phase I/II trial (NCT03333915) pamiparib was recently approved in China for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer previously treated with two or more lines of chemotherapy. This article summarizes the milestones in the development of pamiparib leading to this first approval.

• Authors: Anthony Markham
• Journal: Drugs (Drugs) Vol. 81 Issue 11 Pg. 1343-1348 (Jul 2021) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 34287805 (Publication Type: Journal Article, Review)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Fluorenes
• Poly(ADP-ribose) Polymerase Inhibitors
• pamiparib

Topics

• Area Under Curve
• China
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Drug Approval
• Female
• Fluorenes (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Half-Life
• Humans
• Ovarian Neoplasms (drug therapy)
• Peritoneal Neoplasms (drug therapy)
• Poly(ADP-ribose) Polymerase Inhibitors (adverse effects, pharmacokinetics, pharmacology, therapeutic use)